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Abstract
Background: RotaTeq™ (RV5; Merck & Co. Inc., USA) and Rotarix™ (RV1, GlaxoSmithKline, Belgium) vaccines,
developed to prevent rotavirus diarrhea in children under five years old, were both introduced into national
immunization programs in 2006. As many countries in Latin America and the Caribbean have included either RV5
or RV1 in their routine childhood vaccination programs, we conducted a systematic review and meta-analysis to
analyze efficacy, safety and effectiveness data from the region.
Methods: We conducted a systematic search in PubMed, EMBASE, Scielo, Lilacs and the Cochrane Central Register,
for controlled efficacy, safety and effectiveness studies published between January 2000 until December 2011, on
RV5 and RV1 across Latin America (where both vaccines are available since 2006). The primary outcome measures
were: rotavirus-related gastroenteritis of any severity; rotavirus emergency department visits and hospitalization; and
severe adverse events.
Results: The results of the meta-analysis for efficacy show that RV1 reduced the risk of any-severity rotavirus-related
gastroenteritis by 65% (relative risk (RR) 0.35, 95% confidence interval (CI) 0.25; 0.50), and of severe gastroenteritis by
82% (RR 0.18, 95%CI 0.12; 0.26) versus placebo. In trials, both vaccines significantly reduced the risk of hospitalization
and emergency visits by 85% (RR 0.15, 95%CI 0.09; 0.25) for RV1 and by 90% (RR 0.099, 95%CI 0.012; 0.77) for RV5.
Vaccination with RV5 or RV1 did not increase the risk of death, intussusception, or other severe adverse events which
were previously associated with the first licensed rotavirus vaccine. Real-world effectiveness studies showed that both
vaccines reduced rotavirus hospitalization in the region by around 45–50% for RV5 (for 1 to 3 doses, respectively), and,
by around 50–80% for RV1 (for 1 to 2 doses, respectively). For RV1, effectiveness against hospitalization was highest
(around 80–96%) for children vaccinated before 12 months of age, compared with 5–60% effectiveness in older
children. Both vaccines were most effective in preventing more severe gastroenteritis (70% for RV5 and 80–90% for
RV1) and severe gastroenteritis (50% for RV5 and 70–80% for RV1).
Conclusion: This systematic literature review confirms rotavirus vaccination has been proven effective and well
tolerated in protecting children in Latin America and the Caribbean.
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Background
Diarrheal diseases are the second most common cause
of mortality in children under five years of age [1]. In-
deed, an estimated 2.5 billion children suffer from diar-
rheal diseases and 1.5 million children die worldwide
from diarrhea every year. Most cases occur in developing
nations [1]. The most common etiological agent of acute
infectious diarrhea in children under five years old is
rotavirus [2]. In fact, approximately one third of fatal
diarrheal cases, estimated in 2008 as 453,000 children
per year, mostly in less developed countries [3] and 40%
of hospital admissions, due to diarrhea among children
under five years of age, were caused by rotaviruses [1].
Severe rotavirus gastroenteritis is largely limited to chil-
dren aged 6–24 months. Additionally, in developing
countries, three-quarters of children suffer their first
rotavirus diarrhea episode before 12 months of age [4].
Reinfections are common as mild diarrhea or asymp-
tomatic infections [5]. Several studies have shown that
immunization helps to reduce the number of diarrhea-
associated deaths by preventing rotavirus infections or
by reducing their severity [6].
The first licensed rotavirus vaccine was RotaShield™
(Wyeth Laboratories, Inc., Marietta, Pennsylvania, USA),
with 80–100% efficacy in preventing severe rotavirus
diarrhea in randomized clinical trials [7–9]. Although
licensed for routine use in the United States in 1998, it
was soon withdrawn from the market due to an in-
creased risk of intussusception, estimated at 10–20 cases
per 100,000 doses [10–12]. Two new rotavirus vaccines
with different antigen compositions and dosing schedules
have been approved for human use since 2006 in several
countries, including 17 developing countries in Latin
America and the Caribbean region [13, 14], where an esti-
mated 88 deaths per 100,000 children under 5 years occur
annually [15]. RV5 (RotaTeq™; Merck & Co., Inc., West
Point, PA, USA) is a three-dose oral pentavalent (G1, G2,
G3, G4, P8) bovine-human reassortant vaccine, adminis-
tered at 6–12 weeks of age, with a gap of 4–10 weeks
between subsequent doses. RV1 (Rotarix™ RIX4414;
GlaxoSmithKline, Belgium), is a two-dose oral monovalent
human attenuated vaccine derived from a G1[P8] virus
[4], administered at 8 and 16 weeks of age. The WHO rec-
ommended both vaccines for routine child immunization
globally, based on trial results [16–18], with surveillance
and long term monitoring for intussusception and other
potential health problems [19].
The aim of the present work was to conduct a system-
atic review and meta-analysis on the efficacy, safety, and
effectiveness of RV5 and RV1 in Latin America and the
Caribbean. These analyses will benefit from the early
introduction of the vaccine in these developing nations
where mortality from rotavirus disease is highest [20].
Vaccine effectiveness studies provide real world data on
outcomes and safety, and, meaningful long term public
health data. The findings will be useful to guide
decision-making with respect to the continuation, ad-
justment and expansion of rotavirus vaccine programs in
developing countries.
Methods
We carried out a systematic review and meta-analysis to
describe, compare and summarize the vaccine efficacy,
from pre-licensure randomized clinical trials, and vac-
cine effectiveness, from post-licensure comparative ob-
servational studies, of RV5 and RV1, in preventing
rotavirus gastroenteritis and reducing hospitalization
and emergency visits across Latin American countries,
where both vaccines have been available for the last dec-
ade. In addition, safety data of RV5 and RV1 were col-
lected to assess the risk of intussusception, severe adverse
events or death potentially associated with vaccination.
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses, PRISMA Statement [21] in
the conduct of this review.
Data collection and analysis
Database search strategy
We conducted a sensitive and systematic search in the
following electronic databases: PubMed, EMBASE,
Scielo, Lilacs and the Cochrane Central Register for
Controlled Trials. We used the free and Medical Subject
Heading (MeSh) search terms, Boolean operators, time
limits and methodological filters available on each data-
base. The search strategy is fully described in Additional
file 1: web-appendix 1 of the supplementary material.
Articles published between January 2000 until December
2011 were considered in the review and no language
limitation was applied.
Study screening and data extraction
After selecting the records, three independent reviewers
applied inclusion criteria to assess the eligibility of ab-
stracts and full-text papers, according to the settings
shown in Additional file 1: web-appendix 2. Briefly, for
the efficacy and safety evaluation, only randomized clin-
ical trials including an experimental group receiving
RV5 or RV1 were included. Case–control studies evalu-
ating effectiveness were included if one group was
exposed to either licensed vaccine. The evaluated popu-
lation exclusively included children under five years old
from Latin America and the Caribbean region. The
primary outcome measures included: rotavirus-related
gastroenteritis of any severity; emergency department
visits and hospitalization due to rotavirus; and severe
adverse events (see Additional file 1: web-appendix 2).
Rotavirus gastroenteritis severity was based on the Vesikari
Clinical Severity Scoring System that includes assessment
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of diarrhea, vomiting, temperature, dehydration and treat-
ment [22, 23]. The scale, from 0 to 20, was used to relate to
severity as such; scores above 11 were considered ‘severe’,
and above 19 were considered ‘more severe’, as in a previ-
ous study.
Reviewers used a standard eligibility form based on
the inclusion criteria. Publications that were duplicate or
described studies that did not fulfill the inclusion criteria,
as well as editorials were excluded from the analysis. Re-
viewers collected data on vaccine type and dose, number
of participants in each group, dropouts or withdrawals,
duration of follow-up, type of population and frequency of
the defined outcome on pre-tested data extraction sheets
(Additional file 1: web-appendix 3). When the reviewers
disagreed about the evaluation of eligibility, either a fourth
reviewer was consulted or a re-evaluation was done until
consensus was achieved.
Assessment of the risk of bias in included studies
For the efficacy and safety evaluation, two independent
and masked reviewers assessed the risk of bias of the in-
cluded studies, according to the Cochrane Collaboration
criteria [24]. These criteria consider: sequence gener-
ation, blinding of participants and personnel, blinding of
outcome, data integrity, and selective outcome reporting.
Reviewers used a standard form for risk of bias evaluation
(see Additional file 1: web-appendix 4). A judgment about
the summary risk of bias per study was made (see
Additional file 1: web-appendix 6) based on the individual
bias assessments within each study. Disagreements were
solved by consensus.
Statistical analysis
Efficacy of the vaccines was defined as the relative risk
reduction calculated as (1− relative risk) × 100, obtained
from data corresponding to randomized clinical trials.
However, since the meta-analysis was performed with
relative risk, the forest plots and the description of the
results are presented as the calculated % efficacy and the
estimated relative risk with the calculated 95% Confi-
dence Intervals (95% CI). For studies not included in the
meta-analysis, only the percentage of efficacy (95% CI) is
presented. For safety, the strength of association between
rotavirus immunization and a) intussusception, b) severe
adverse events, and c) mortality caused or associated to
vaccination was assessed by calculating the relative risk and
95% CI. Effectiveness was reported as (1–Odds Ratio) x 100
in the case–control studies.
Summary relative risk was calculated from the meta-
analysis. A fixed-effect model (Mantel-Haenszel method
[25]), assuming trial homogeneity, and a random-effects
model (DerSimonian and Laird method [26]), accounting
for trial heterogeneity, were used.
Results were reported with the random-effects model
if there were differences between trials influencing the
size of the treatment effect or when heterogeneity was
detected. This was only applicable to the efficacy esti-
mate. The Chi-squared (χ2) test was applied to deter-
mine heterogeneity (p <0.10 was considered significant)
and the I2 statistic to quantify inconsistency across trials
(I2 > 50% indicated heterogeneity). On the contrary, for
effectiveness estimates, only summary figures are pre-
sented since there were differences in study designs
making it difficult for the individual study to meet the
criteria to be eligible for the meta-analysis. Analyses
were performed using Statistical Analysis System 9.0
(SAS, SAS Institute, Cary, NY, USA).
Results
Efficacy and safety assessment
Study selection
Nine out of the 234 reviewed citations fulfilled the eligibil-
ity criteria described in Additional file 1: web-appendix 2.
The selection of the included literature is depicted as a
flow diagram in Fig. 1 (for detailed information of the in-
cluded studies see Additional file 1: web-appendix 5). Data
from five studies were included from the original publica-
tions as well as from four subsequent publications focus-
ing on specific subsets of countries within the global trials,
or on longer term follow up data.
Risk of bias of included studies
The assessment of partiality during the selection of the lit-
erature indicated that blind assignment and outcome were
the main bias sources in this study. The bias risk summary
of the nine evaluated studies was low in 22% and moderate
in 78% of the cases (see Additional file 1: web-appendix 6).
Description of selected studies
Two publications evaluated RV5 from one large trial of
4,489 participants [27] and a sub-study of the trial in
1,650 children in Jamaica (high quality evidence) [28].
Seven publications assessed RV1 in 26,342 children from
four original trials [17, 18, 29, 30] and 15,326 children
from three sub-studies of these trials (high quality evi-
dence) [31–33].
Studies were conducted in 15 different countries. For
RV1: Brazil (5), Colombia and Mexico (4), Argentina,
Dominican Republic, Honduras, Panama and Venezuela
(3), Chile and Nicaragua (2) and Peru (1); for RV5:
Jamaica (2) and Costa Rica, Guatemala, Mexico and
Puerto Rico (1).
General descriptive information concerning the type of
rotavirus vaccine, vaccination schedule and dose, loca-
tion, population size, duration of follow-up, participants’
age and outcome is provided in Additional file 1:
web-appendix 7.
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Efficacy of rotavirus vaccines
Rotavirus vaccination reduced hospital admissions
and emergency department visits A pre-licensure
study across several regions assessed the efficacy of RV5
based on the combined reduction of hospitalizations and
visits to the emergency department associated with rota-
virus gastroenteritis. Within the Latin America and
Caribbean region, the study described 90% efficacy of
RV5 (relative risk 0.099, 95% CI: 0.012–0.77, 4,489
participants, one trial, Analysis 1.1 in Fig. 2) [27]. In
a sub-study of Jamaican children, not included in
meta-analysis because they were evaluated globally in
the larger trial, a reduction of 82.2% (95% CI: 15.1 to 98)
in hospitalizations, or emergency department visits attrib-
utable to rotavirus gastroenteritis involving any serotype,
was found after three doses of RV5 [28].
Pooled data from three pre-licensure studies [17, 18, 30]
showed that during one year of follow up, RV1 reduced
hospital admissions due to severe rotavirus gastroenteritis
by 85% (relative risk 0.15, 95% CI: 0.09–0.25, 26,023
participants, Analysis 1.2 in Fig. 2). A similar efficacy
percentage was reported for RV1 in preventing
rotavirus-related gastroenteritis hospitalizations in two
additional sub-studies (not included in this meta-
analysis) conducted across Latin America (83%; 95%
CI: 73.1–89.7) [33] after a 2-years follow up, and in
Brazil (80.3%; 95% CI: 51.1–92.5) [31].
Rotavirus vaccination decreased both diarrhea of any
cause and rotavirus-related gastroenteritis RV1 re-
duced the occurrence of diarrhea of any cause by 37% in
vaccinated children as compared to those receiving pla-
cebo, during the first year following vaccination (relative
risk 0.63; 95% CI: 0.54–0.74; 24,177 participants, 2 trials,
Analysis 3.1 in Fig. 3) [18, 30]. A sub-study, not included
in this meta-analysis, reported a similar result but during
the second year of follow up (efficacy 39%; 95% CI:
30.1–46.9) [33]. RV1 reduced the overall presentation of
not only diarrheal disease, but specifically for rotavirus
gastroenteritis of any severity by 65% (relative risk 0.35;
95% CI: 0.25–0.50; 2,165 participants, 2 trials, Analysis
3.2 in Fig. 3) [18, 30]. This percentage differed from sub-
studies not included in the meta-analysis and conducted
in Mexico (76.3%; 95% CI: 48.9–89.3) [32] and Brazil
(43.5%; 95% CI: 48.9–89.3) [31]. Finally, RV1 reduced
the frequency of severe rotavirus gastroenteritis by 82%
Fig. 1 PRISMA flow chart: rotavirus vaccine efficacy and safety. Combined PRISMA* flow chart for the systematic review to evaluate rotavirus
vaccine efficacy and safety in countries from Latin America and the Caribbean
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(relative risk 0.18; 95% CI: 0.12–0.26; 26,342 partici-
pants, 4 trials, Analysis 3.3 in Fig. 3) [17, 18, 29, 30].
This estimate was close to that reported for Latin
American children after a two year-follow up (79%; 95%
CI: 66.4–87.4) [33] and Mexican children (90%; 95% CI:
66.4–87.4) [32], but greater than the one reported in
Brazil (64.5%; 95% CI: 30.7–81.7) [29]; once again these
three sub-studies were not included in the meta-analysis
since they were evaluated in a previous larger trial.
Safety of rotavirus vaccines
Rotavirus vaccination did not increase the risk of
death, intussusception or other severe adverse events
Safety evaluations were not frequently reported for the
pre-licensure studies included in this meta-analysis (see
Additional file 1: web-appendix 7). Where reported, RV1
did not increase the risk of death across the vaccinated
children (relative risk 1.34; 95% CI: 0.92–1.96; 71,690
participants, 3 trials, Analysis 4.1 in Additional file 1:
web-appendix 9) [17, 18, 30]. Similarly, in the Jamaican
trial with RV5, none of the four deaths (1 vaccinated in-
fant and 3 placebo recipients) were vaccine-related [28].
Pooled data for RV1 showed no increased risk of intus-
susception among vaccinated children (relative risk 0.64;
95% CI: 0.31–1.34; 71,690 participants, 3 trials, Analysis
5.1 in Additional file 1: web-appendix 10) [17, 18, 30]. In
the RV5 studies, there was only one confirmed case of in-
tussusception in a RV5 recipient, compared to three cases
in the placebo group [28].
Three pre-licensure studies evaluated the association
of RV1 with severe adverse events [17, 18, 30]; a list of
the most frequent severe adverse events reported in
these studies is presented in Additional file 1: web-
appendix 11. The pooled results indicated no increased
risk in the occurrence of severe outcomes in RV1-
immunized children as compared to controls (relative
risk 0.89; 95% CI: 0.83–0.95; 71,690 participants, 3 trials,
Analysis 6.1 in Additional file 1: web-appendix 12) [17,
18, 30]. Only one study evaluated severe adverse events
and the use of RV5 [28]. In this study, severe adverse
outcomes were reported in 3.5% (31/898) and 4.8%
(43/904) vaccinated or placebo exposed children, re-
spectively. Only single cases of febrile infection and
gastroenteritis were associated with RV5.
Effectiveness and impact assessment
Study selection
Of the 691 citations identified, 45 full text articles were
screened and 23 were identified for analysis. Of the 23
publications, four case–control studies assessing vaccine
effectiveness were included for analysis. The remaining
studies used various methods to assess the impact of
vaccination (see Fig. 4, Additional file 1: web-appendix 2
and 13 for details).
Description of selected studies
The effectiveness of RV5 was evaluated in one study
in Nicaragua, and effectiveness of RV1, in two studies
Fig. 2 Forest plot: Hospitalization or emergency visits for rotavirus gastroenteritis in trials. Forest plot of meta-analysis for hospitalization or emergency
unit visit due to rotavirus gastroenteritis in trials. Rotavirus vaccination vs. placebo: relative risk for requiring hospitalization or emergency unit visit due
to rotavirus gastroenteritis
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in Brazil and one in El Salvador. Both, the summary
of the characteristics and the main results of these
studies stratified by design and vaccine type are pre-
sented in Additional file 1: web-appendix 14 and 15,
respectively.
Effectiveness and impact of rotavirus vaccines
Rotavirus vaccines reduced the likelihood of rotavirus
infection, gastroenteritis-related hospitalization and
death in children under five years of age Four case–
control studies assessed the effectiveness of RV1 (3) and
RV5 (1) against severe rotavirus gastroenteritis and hos-
pitalizations/emergency visits due to rotavirus [34–37].
Effectiveness was evaluated by comparing: immunization
scheme (partial vs. full-dose administration), age at
immunization (<12 months vs. >12 months of age) or
the reduction in the severity of the rotavirus-related
gastroenteritis (Fig. 5).
One study evaluating RV5 in children from Nicaragua
[34] showed similar vaccine effectiveness against
hospitalization when partial or full three-dose schedules
were administered (range from 45 to 50%, Fig. 5a).
However, for subjects fully vaccinated with RV5,
effectiveness against moderate, severe and more se-
vere rotavirus-related episodes of diarrhea increased
according to disease severity (23, 52 and 73% effect-
iveness, respectively; Fig. 5c).
RV1 effectiveness against hospitalization was highest
when administered under a two-dose scheme (range
from 75.8 to 81%, Fig. 5a), as well as when full vac-
cination was administered to children under the age
of twelve months (range from 81 to 95.7%, Fig. 5b)
[35–37]. If administered according to a one-dose
scheme, the effectiveness of RV1 in preventing hos-
pital admission due to rotavirus ranged from 51 to
62.3% (Fig. 5a). However, the protecting effect dimin-
ished in vaccinated children over one year of age
(range from 5 to 65.1%, Fig. 5b). Additionally, full
immunization with RV1 increased the effectiveness
against presenting more severe rotavirus gastroenteritis
(range from 83 to 90%) in comparison to less severe
rotavirus-related gastroenteritis (Fig. 5c).
Fig. 3 Forest plot: Severe diarrhea, rotavirus gastroenteritis (any severity) and severe rotavirus gastroenteritis in trials. Forest plot of meta-analysis
for preventing rotavirus gastroenteritis of any severity in trials. Rotavirus vaccination vs. placebo: relative risk for protecting against rotavirus
gastroenteritis of any severity or severe rotavirus gastroenteritis
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Fig. 4 PRISMA flow chart: rotavirus vaccine effectiveness. PRISMA* flow chart for the systematic review to evaluate rotavirus vaccine effectiveness
in countries from Latin America and the Caribbean
Fig. 5 Effectiveness of RotaTeq™ and Rotarix™ vaccines in preventing rotavirus-related hospital admissions or rotavirus gastroenteritis. Effectiveness
of RotaTeq™ and Rotarix™ vaccines in preventing rotavirus-related hospital admissions or rotavirus gastroenteritis according to (a) partial or full
vaccination scheme, (b) age at immunization, and (c) severity of the disease. a Neighborhood controls, b Rotavirus negative control participants
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This review also identified a number of studies with
different designs (i.e., cohort, cross-sectional and eco-
logical) which assessed the impact of vaccination in the
population in different ways. These will be the subject of
a separate publication.
Discussion
RV5 and RV1 were first introduced to the immunization
programs of several developed and developing countries
in the last decade. This seemed to be the ideal time to
conduct a systematic review and meta-analysis to evalu-
ate the long-term benefits and impact of implementing
massive vaccination programs with both vaccines in
Latin America, from the period when the vaccines were
first introduced. We gathered published information on
the efficacy, safety and effectiveness of both vaccines in
Latin American and Caribbean children between 2000
and 2011. Having conducted a thorough selection
process and literature analysis, we conclude that RV5
and RV1 have significantly reduced hospital admissions
and emergency department visits, the frequency of diar-
rheal disease of any cause and rotavirus-related gastro-
enteritis and the likelihood of children of getting infected
by rotavirus over time. Pre-licensure studies with RV5 or
RV1 did not show an increase in the frequency of intus-
susception and other severe adverse events, previously
associated with rotavirus immunization. Vaccination did
not increase the risk of death among children. In general,
protection against rotavirus gastroenteritis was greater if
vaccination occurred during the first year of life and was
administered according to the recommended schedule
and doses. Hence, over the last decade, vaccination with
RV5 and RV1 has proven to be effective, safe, and efficient
in protecting children under five years of age across Latin
America and the Caribbean.
Several recent studies suggest that RV1 and RV5 could
be associated with a slight increase in the risk of develop-
ing intussusception. Both RV1 and RV5 were associated
with approximately 1 to 6 excess cases of intussusception
per 100,000 recipients following the first dose in Mexico,
the United States and Australia [38–40]. A smaller pro-
portion was detected after the second vaccine dose in
Brazil [41]. Nevertheless, this estimate is still several times
lower than the risk of intussusception reported for Rota-
Shield™ [42, 43]. On the other hand, a study from
Germany reports an increased risk of intussusception in
infants only if the first dose of rotavirus vaccine is admin-
istered after 90 days of age [44]. For this reason, some au-
thors [45] have proposed a re-evaluation of the age-limit
for the administration of the first dose of vaccine from
16 weeks to the original 12 week age-limit recommended
by manufacturers. Conversely it can be argued that there
is insufficient evidence to suggest that the risk of intussus-
ception is lower in children vaccinated at an earlier age
and that an extended vaccination window may increase
vaccine coverage and its benefits, especially in developing
countries where not all of the children receive vaccination
according to the recommended dosing schedules [45].
Taking all these considerations into account it was esti-
mated that the benefits of rotavirus vaccination against
diarrhea hospitalizations and death from rotavirus infec-
tion far exceeded the risk of intussusception [46]. Hence,
WHO has recommended keeping the rotavirus vaccines
in all national immunization programs worldwide [19].
At the present time, 19 countries and territories in
Latin America and the Caribbean include rotavirus vac-
cines in their national immunization programs [47].
Most use RV1 [13], which therefore provides the major-
ity of the post-marketing evidence. Many studies were
conducted in Brazil and Mexico, followed by Panama,
Venezuela, Nicaragua and Honduras. The vaccines’ effi-
cacy values from clinical trials against rotavirus gastro-
enteritis hospitalizations were between 85 and 90%
(Fig. 2); RV1 was around 80% effective against severe
rotavirus gastroenteritis (Fig. 3). The overall reported ef-
fectiveness in the region against more severe rotavirus
gastroenteritis was of 73% for RV5 and 83% for RV1
(Fig. 5c). The effectiveness of RV5 against severe rotavirus
gastroenteritis was 52% (Fig. 5c) and the effectiveness of
RV1 against rotavirus gastroenteritis hospitalizations is be-
tween 76 and 96% (Fig. 5a and b). The greatest effect was
seen in children under 12 months of age, as previously ob-
served [48–50], presumably because this represents the
age group targeted for vaccination (Fig. 5b). Also, studies
not included in the meta-analysis indicated a greater mag-
nitude of effectiveness than would be expected from the
proportion of vaccinated children, suggesting an indirect
herd effect [51–55].
The effectiveness estimates demonstrated in this ana-
lysis and those reported in subsequent studies for Latin
American and the Caribbean countries [56–58] are high
and similar to the efficacy values previously observed in
clinical trials. However, they are somewhat lower than
those reported for developed countries, including the
United States [59] and Finland [60]. This is consistent
with previous reports that rotavirus vaccines are more
effective against severe rotavirus gastroenteritis in sub-
regions with very low or low child and adult mortality
[61]. Clinical trials of oral rotavirus vaccines performed
in infants have demonstrated a correlation between vac-
cine efficacy and the socioeconomic level. In high in-
come settings, efficacy exceeds 90%, while in middle (as
are the majority of Latin America and Caribbean coun-
tries) and low income settings the values drop to 80%
[17, 18, 31] and 45% [62–65], respectively. Although the
reasons for this phenomenon are unclear, a range of hy-
potheses has been proposed, which include immuno-
logical and epidemiologic factors including nutritional
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status [66, 67], concomitant infection, greater diversity
of rotavirus strains circulating in many developing coun-
tries [68], as well as socioeconomic conditions affecting
health care access. It has also been shown that vitamin A
deficiency impairs immune responses to rotavirus vaccines
in animal models [69, 70]. However, since most of the
rotavirus-associated fatalities occur in low income coun-
tries [20], despite the lower vaccine efficacy, the number
of severe disease cases and deaths prevented by vaccines
are likely to be higher than in high income countries.
Although rotavirus vaccines were developed from the
most common circulating rotavirus strains, it has been
observed that they also confer protection against other
strains [17, 71, 72], suggesting an important role for het-
erotypic protective immunity. According to this observa-
tion, both commercially available vaccines have been
shown to be highly effective against severe rotavirus
disease, despite one being monovalent and the other penta-
valent [59, 73]. This is important because data from coun-
tries in Asia and Africa show greater strain diversity with
several rotavirus types circulating simultaneously [74].
There are a few limitations of this review that should
be taken into account when analyzing the findings con-
solidated and presented here, especially if comparisons
between vaccines or between the outcomes observed in
each country are to be made. Firstly, because many of
the studies did not fulfill the eligibility criteria for inclu-
sion in the meta-analysis, the final dataset comprised
very few studies which were not representative of the
Latin American and Caribbean region. Additionally, the
type of methodology employed to determine vaccination
program outcomes considered in this analysis, used the
screening method to assess the vaccine effectiveness. For
example, where there are discrepancies in the data re-
ported for the same country [50]. This analysis focused
on studies published between 2000 and 2011, an update
to this review is warranted for further research.
Lastly, both vaccines are not equally represented in
the included studies. We have data for RV5 from just 2
of the 9 efficacy studies and 1 of the 4 studies for effective-
ness. This is due to the distribution of the vaccines in
Latin American and Caribbean countries, where the ma-
jority of the clinical trials were conducted using RV1 vac-
cine and where most countries are using this vaccine in
their immunization program. This prevents a fair com-
parison of the outcomes of each vaccine in this region.
However, in countries where both vaccines are routinely
used, similar efficacy and effectiveness has been reported
[59, 73, 75], which is consistent with the results of this
meta-analysis. Therefore, despite all the aforementioned
considerations, the results obtained from this meta-
analysis are consistent with other studies and provide a
general panorama of the outcomes of the implementation
of rotavirus vaccination in Latin America and the
Caribbean region. This information is fundamental in de-
ciding whether the vaccination programs should be con-
tinued and gives a solid foundation for considering the
expansion of these programs to other developing nations.
One of the most important aspects when analyzing the
viability of a vaccine program implementation is cost-
effectiveness. Although cost-effectiveness ratios vary
from one country to another [76], universal vaccination
of infants has been demonstrated to be cost-effective for
both rotavirus vaccines, especially for middle and low in-
come settings [19, 77]. Other vaccine characteristics,
such as the number of doses or the presentation, may be
taken into account when selecting the most appropriate
vaccine to meet the special conditions for each country.
Conclusion
Evidence accumulated since the implementation of rota-
virus vaccination in Latin America and the Caribbean al-
lows us to conclude that the current vaccines are effective
in reducing the risk of hospitalization and death due to
rotavirus infection and all-cause gastroenteritis. Irrespect-
ive of the implementation plan for rotavirus vaccination, a
coordinated strategy for the prevention and treatment of
childhood diarrhea will also require improvements in hy-
giene and sanitation levels, as well as awareness of and ac-
cess to oral rehydration therapy, zinc supplementation
and other effective treatments. Lastly, the benefits from
rotavirus vaccination greatly exceed the risk of intussus-
ception, especially in developing regions such as Latin
America. Nonetheless, it is recommended to continue
monitoring in countries where rotavirus vaccines are used.
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